ArticleiMeta2025

Efficacy and biomarker analysis of neoadjuvant disitamab vedotin (RC48-ADC) combined immunotherapy in patients with muscle-invasive bladder cancer: A multi-center real-world study.

Jiao Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.